Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan

Atypical hemolytic uremic syndrome is a rare, life-threatening disorder which can be triggered by COVID 19 infection and COVID 19 vaccination then induce multiple organ failure. Our study is the first to evaluate immune responses to COVID-19 vaccination and safety in a cohort of patients in a local single-center study in Taiwan.. Results indicate that vaccines effectively shield aHUS patients from severe COVID-19 complications without significant safety concerns. A double booster dose for the third vaccine is essential for optimal efficacy. Anti complement therapy did not influence vaccination effectiveness. Transplant aHUS patients had the lowest immune response titers, indicating a need for additional vaccine doses. Compared to healthcare workers, aHUS patients had poor T-cell responses. We noted a superior trend with mixed-type COVID-19 vaccinations in aHUS patients, while fixed-type mRNA demonstrated better results in healthcare workers. Our findings endorse COVID19 vaccination as a potent strategy to safeguard aHUS patients from severe complications, emphasizing the importance of vigilant monitoring pre-and post-vaccination.

Automated summary

This study evaluated the immune responses and safety of COVID-19 vaccination in patients with atypical hemolytic uremic syndrome (aHUS) in Taiwan. The results showed that the vaccines effectively protected aHUS patients from severe COVID-19 complications without significant safety concerns. Transplant aHUS patients had lower immune response titers, indicating a need for additional vaccine doses.